Dr. Yuxiang Wang, Fudan University, China
Dr. Yuxiang Wang is a Principal Investigator and Ph.D. Supervisor at Fudan University, with an extensive background in molecular biology, oncology, and translational medicine. He earned his Ph.D. in Developmental and Molecular Biology from the Albert Einstein College of Medicine, where he worked under the mentorship of Dr. Jeffrey W. Pollard. Following this, he completed a prestigious research fellowship at Memorial Sloan-Kettering Cancer Center. Dr. Wang has built a strong academic and clinical research portfolio, focusing on gliomas and muscular dystrophy. His work utilizes state-of-the-art preclinical models and CRISPR screening technologies to identify novel therapeutic strategies. Dr. Wang is a recipient of numerous honors, including the MSK Society Scholar Award and Shanghai Leading Overseas Talent recognition. He actively collaborates with clinicians to translate lab discoveries into patient therapies, and his prolific publication record reflects deep scientific rigor and innovation.
Publication Profile:
Scopus
✅ Strengths for the Award:
-
Strong Research Track Record
Dr. Wang has published in top-tier journals such as Nature Communications, Science Advances, Cancer Research, and PNAS. His publication record demonstrates consistency, depth, and high impact across multiple domains including glioma biology and gene therapy.
-
Dual Research Focus
He leads research in two distinct yet critical biomedical areas—malignant gliomas and muscular dystrophy. This breadth shows versatility and the ability to manage complex translational programs.
-
Innovative Techniques
Dr. Wang effectively applies CRISPR-based genetic screening, preclinical mouse models, and patient-derived cell lines—cutting-edge tools that reflect a forward-thinking, high-tech research approach.
-
International Research Background
His training and professional experience in both the U.S. (at Memorial Sloan-Kettering Cancer Center) and China make him a bridge between Western and Eastern biomedical research ecosystems.
-
Leadership and Mentorship
Serving as both Principal Investigator and Ph.D. Supervisor, and having been Vice Director at a major clinical research center, Dr. Wang shows strong leadership and a commitment to research training.
-
Recognitions and Awards
Prestigious honors such as the Shanghai Leading Overseas Talent, Shanghai Pujiang Talent, and MSK Society Scholar Award (twice) underline peer recognition and scientific excellence.
🛠️ Areas for Improvement:
-
Clinical Translation and Implementation
While his preclinical work is strong, more details or evidence on how these findings have progressed toward clinical trials or therapeutic products could further strengthen his translational profile.
-
Interdisciplinary Collaborations
Expanding collaborations across fields like bioengineering, immunotherapy, or computational biology may add further value and broaden research impact.
-
Visibility and Outreach
Increasing visibility through keynote lectures, patents, or public datasets could enhance his reputation globally and support broader dissemination of his work.
-
Grants and Funding Portfolio
While not detailed in the CV, highlighting national/international grant leadership or participation would provide insight into his ability to secure and manage competitive research funding.
🎓 Education:
Dr. Yuxiang Wang holds a distinguished academic background across leading institutions. He completed his Ph.D. in Developmental and Molecular Biology at Albert Einstein College of Medicine (2008–2014), under Dr. Jeffrey W. Pollard, focusing on hormone signaling and uterine biology. Before that, he earned a Master of Sciences from Fudan University (2004–2007), mentored by Dr. Bo Chen, where he explored hormone interactions in reproductive biology. He began his academic journey with a Bachelor of Sciences from the Ocean University of China (2000–2004), majoring in life sciences. This robust education laid the foundation for his later success in cancer biology and translational research. Throughout his academic path, Dr. Wang has demonstrated a consistent focus on the cellular and molecular mechanisms underlying human diseases, especially cancer and genetic disorders. His education, blending rigorous laboratory work and clinical relevance, has uniquely positioned him for cutting-edge biomedical research.
💼 Experience:
Dr. Wang currently serves as Principal Investigator and Ph.D. Supervisor at Fudan University’s School of Basic Medical Sciences (2020–present), where he leads research on gliomas and muscular dystrophy. From 2021 to 2023, he also held the position of Vice Director of the Research Department at the Clinical Research Center of the Affiliated Children’s Hospital of Fudan University, coordinating clinical and translational projects. Prior to his return to China, Dr. Wang worked as a Research Fellow at Memorial Sloan-Kettering Cancer Center (2015–2020), collaborating with Dr. Timothy Chan and Dr. Jason Huse on the molecular basis of brain tumors and treatment resistance. His career bridges fundamental science and clinical applications, with a focus on leveraging genetic models and CRISPR technologies to uncover therapeutic targets. Dr. Wang’s international experience and leadership in high-impact research programs underscore his contributions to biomedical innovation and mentorship.
🏅 Awards and Honors:
Dr. Yuxiang Wang’s outstanding scientific contributions have been recognized through several prestigious awards. He was named a Shanghai Leading Overseas Talent (2020) and a Shanghai Pujiang Talent (2020), highlighting his excellence in international scientific exchange and leadership. While at Memorial Sloan-Kettering Cancer Center, he was twice awarded the MSK Society Scholar Award (2018, 2019), which recognizes exceptional postdoctoral researchers demonstrating strong potential for independent academic careers. These accolades underscore Dr. Wang’s commitment to impactful research, innovation in therapeutic development, and mentorship of young scientists. His ability to translate fundamental research into preclinical and potentially clinical solutions sets him apart as a research leader. These honors reflect peer recognition of both the depth and translational potential of his work in oncology and genetic diseases.
🔬 Research Focus:
Dr. Wang’s research centers on two critical areas: malignant gliomas and muscular dystrophy. In glioma studies, his team investigates the cooperative role of IDH and ATRX mutations using CRISPR-based genetic screening in mouse models to identify synthetic lethal targets—genes whose inhibition can selectively kill tumor cells with specific mutations. This strategy opens doors to novel, mutation-specific therapies with minimal harm to healthy cells. In muscular dystrophy, Dr. Wang focuses on rare genetic mutations affecting glycosylation pathways, utilizing patient-derived cells and animal models to evaluate gene therapy and genome editing solutions. His work seeks not only to understand disease mechanisms but also to bridge the lab-to-clinic gap. A long-term objective is to offer personalized therapies for patients with genetically defined diseases. The integration of molecular biology, translational research, and therapeutic innovation defines his approach.
📚 Publication Top Notes:
-
🧬 Genetically Engineered Mouse Models Unveil Mechanisms and Therapeutic Strategies for GMPPB-Associated Dystroglycanopathy – Nature Communications (under revision)
-
🧠 PRICKLE4 Underlies IDH mutant Tumor Resistance against PARP Inhibition – Advanced Science (under revision)
-
🧫 Comprehensively characterizing eRNA in immune cells to screen combinational strategies for anti-cancer immunotherapy – Cancer Research (2025)
-
🔬 Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas – Science Advances
-
🧬 G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma – Nature Communications
-
🧪 Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence – Nature Genetics
-
🧠 Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling – Nature Communications
-
🧬 Activation of protein synthesis in mouse uterine epithelial cells by estradiol-17β is mediated by a PKC–ERK1/2–mTOR signaling pathway – PNAS
-
🔬 GSK-3β mediates in the progesterone inhibition of estrogen-induced cyclin D2 nuclear localization and cell proliferation in cyclin D1−/− mouse uterine epithelium – FEBS Letters
🧾 Conclusion:
Dr. Yuxiang Wang is a highly deserving candidate for the Best Researcher Award. He demonstrates:
-
A clear and sustained record of scientific excellence,
-
Deep expertise in cancer biology and rare disease genetics,
-
Use of innovative methodologies, and
-
Leadership in both academic and clinical research environments.
His contributions to understanding the molecular basis of gliomas and developing targeted therapies for muscular dystrophy have significant implications for personalized medicine. With continued development in clinical translation and interdisciplinary reach, he stands out as a leader of the next generation of biomedical scientists.